Ascelia Pharma Logo

Ascelia Pharma

Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.

ACE | ST

Overview

Corporate Details

ISIN(s):
SE0010573113 (+2 more)
LEI:
5493002YR9VCJJPWYN08
Country:
Sweden
Address:
Hyllie Boulevard 34, 215 32 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for rare oncology conditions, addressing unmet medical needs. The company's lead drug candidate, Orviglance®, is a novel, non-gadolinium-based oral contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly for cancer patients with severely impaired kidney function who cannot use existing gadolinium-based agents. Ascelia Pharma is advancing its pipeline through late-stage clinical development and the regulatory submission process, including a New Drug Application (NDA) to the U.S. Food and Drug Administration for Orviglance®.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 07:30
Quarterly Report
Swedish 4.2 MB
2025-11-05 07:30
Quarterly Report
English 4.4 MB
2025-11-03 09:55
Board/Management Information
Ascelia Pharma Announces Management Changes to Support Future Growth
English 188.6 KB
2025-11-03 09:55
Board/Management Information
Ascelia Pharma meddelar förändringar i ledningen för att stödja framtida tillvä…
Swedish 189.0 KB
2025-10-23 12:16
Major Shareholding Notification
Swedish 10.9 KB
2025-09-30 07:30
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Ascelia Pharma AB
Swedish 191.1 KB
2025-09-30 07:30
Declaration of Voting Results & Voting Rights Announcements
Change in Number of Shares and Votes in Ascelia Pharma AB
English 190.0 KB
2025-09-24 13:22
Major Shareholding Notification
Swedish 11.1 KB
2025-09-22 20:55
Share Issue/Capital Change
Ascelia Pharma har genomfört en riktad nyemission om cirka 30 MSEK
Swedish 204.3 KB
2025-09-22 20:55
Share Issue/Capital Change
Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Mil…
English 203.5 KB
2025-09-22 17:36
Share Issue/Capital Change
Ascelia Pharma avser att genomföra en riktad nyemission av aktier om cirka 30 M…
Swedish 203.7 KB
2025-09-22 17:36
Share Issue/Capital Change
Ascelia Pharma Intends to Carry Out a Directed Share Issue of Approximately SEK…
English 202.8 KB
2025-09-02 16:10
Share Issue/Capital Change
Fenja Capital II A/S påkallar konvertering av samtliga utestående konvertibler …
Swedish 190.4 KB
2025-09-02 16:10
Share Issue/Capital Change
Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a …
English 190.1 KB
2025-08-21 07:30
Interim Report
Swedish 4.5 MB

Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ascelia Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ascelia Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-22 Marie Birgitta Källström Other Other 18,752 40,316.80 SEK
2025-04-15 Niels Mengel Other Other 92,304 198,453.60 SEK
2025-04-15 Peter Benson Other Other 50,000 107,500.00 SEK
2025-04-15 Carin Linde Other Other 40,328 86,705.20 SEK
2025-04-15 Peter Benson Other Other 21,688 46,629.20 SEK
2025-04-15 Peter Benson Other Other 20,472 44,014.80 SEK
2025-04-15 Julie Brogren Other Other 18,000 38,700.00 SEK
2025-04-15 Peter Benson Other Other 6,152 13,226.80 SEK
2024-09-03 KIBEGEON Other Sell 913,545 150,917.63 SEK
2024-09-03 Niels Mengel Other Sell 131,965 17,815.28 SEK

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.